Share on StockTwits

A number of firms have modified their ratings and price targets on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) recently:

  • Intercept Pharmaceuticals is now covered by analysts at Nomura. They set a “neutral” rating and a $294.00 price target on the stock.
  • Intercept Pharmaceuticals is now covered by analysts at Leerink Swann. They set a “market perform” rating and a $270.00 price target on the stock.
  • Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Summer Street.
  • Intercept Pharmaceuticals is now covered by analysts at RBC Capital. They set an “outperform” rating and a $425.00 price target on the stock.
  • Intercept Pharmaceuticals is now covered by analysts at Goldman Sachs. They set a “neutral” rating and a $265.00 price target on the stock.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) traded up 2.51% during mid-day trading on Wednesday, hitting $254.3699. 263,120 shares of the company’s stock traded hands. Intercept Pharmaceuticals Inc has a 52 week low of $42.41 and a 52 week high of $497.00. The stock has a 50-day moving average of $258.3 and a 200-day moving average of $280.3. The company’s market cap is $5.364 billion.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.